NIH Weekly Funding Opportunities and Policy Notices
Funding Opportunity PAR-23-267 from the NIH Guide for Grants and Contracts. This FOA provides support using the SBIR cooperative agreement mechanisms for the development of novel extracellular vesicle-based therapeutic platforms for use in regenerative medicine. Both native and engineered EVs have demonstrated the ability for specific and targeted tissue and organ repair, which can be harnessed for applications such as extracellular vesicle-based therapeutics. The main objective for this funding opportunity is to support platform-oriented technology development associated with the production, manufacturing, and use, of extracellular vesicles as therapeutics in regenerative medicine.
Funding Opportunity RFA-DA-24-038 from the NIH Guide for Grants and Contracts. This Notice of Funding Opportunity (NOFO) encourages Small Business Technology Transfer (STTR) grant applications from small business concerns (SBCs) proposing research projects directed towards commercialization for the development of novel, evidence-based, FDA-regulated medical products addressing the needs of patients suffering from opioid use disorders (OUD) and/or stimulant use disorders (StUD). Applications received under this NOFO may fall within two scientific areas, namely: (1) pharmacotherapeutics (small molecules and biologics)and (2) medical therapeutic and diagnostic devices, including software as a medical device. This NOFO strives to contribute to the effort against the national opioid and psychostimulant emergency and offer new medical products for individuals, families, and communities affected by this devastating crisis. Small business companies that developed currently marketed technologies or are developing technologies for different indications and are interested in demonstrating that their FDA-regulated product has a potential application in the OUD/StUD space are encouraged to apply.
Funding Opportunity RFA-DA-24-021 from the NIH Guide for Grants and Contracts. The purpose of this Notice of Funding Opportunity (NOFO) is to support basic science experimental studies involving humans that expand our knowledge of theinterrelationships between sleep/circadian rhythms and substance use disorders (SUDs). These mechanistic studies will offer insights into the fundamental processes that link SUDs to disorders of sleep/circadian rhythm and vice-versa, and may also have implications for managing risks associated with developing SUDs and/or identifying new targets for prevention and therapeutics.
Funding Opportunity RFA-DA-24-020 from the NIH Guide for Grants and Contracts. The purpose of this Notice of Funding Opportunity (NOFO) is to support basic science experimental studies that expand our knowledge of theinterrelationships between sleep/circadian rhythms and substance use disorders (SUDs). These mechanistic studies will offer insights into the fundamental processes that link SUDs to disorders of sleep/circadian rhythm and vice-versa, and may also have implications for managing risks associated with developing SUDs and/or identifying new targets for prevention and therapeutics.
Funding Opportunity RFA-HG-23-005 from the NIH Guide for Grants and Contracts. This Notice of Funding Opportunity (NOFO) solicits applications to develop innovative and generalizable statistical methods to enable analysis of data from the human Developmental Genotype-Expression (dGTEx) and non-human primate (NHP dGTEx) projects. Methods that assess the influence of genetic variation on development, compare gene expression and regulation across tissues and time points, or leverage comparative genomics to understand developmental and evolutionary processes and integrate with existing tissue and cell atlas efforts are strongly encouraged. This NOFO is open to all applicants regardless of whether they are currently affiliated with dGTEx, NHP dGTEx, or neither.
Notice NOT-DK-23-013 from the NIH Guide for Grants and Contracts
Notice NOT-HS-23-011 from the NIH Guide for Grants and Contracts
Notice NOT-OD-23-113 from the NIH Guide for Grants and Contracts
Funding Opportunity PAR-23-268 from the NIH Guide for Grants and Contracts. This FOA provides support using the STTR cooperative agreement mechanisms for the development of novel extracellular vesicle-based therapeutic platforms for use in regenerative medicine. Both native and engineered EVs have demonstrated the ability for specific and targeted tissue and organ repair, which can be harnessed for applications such as extracellular vesicle-based therapeutics. The main objective for this funding opportunity is to support platform-oriented technology development associated with the production, manufacturing, and use, of extracellular vesicles as therapeutics in regenerative medicine.
Funding Opportunity PAR-23-156 from the NIH Guide for Grants and Contracts. This FOA encourages applications for the Lasker Clinical Research Scholars Program for the purpose of supporting the research activities during the early stage careers of independent clinical researchers. The program offers the opportunity for a unique bridge between the NIH intramural and extramural research communities and contains two phases. In the first phase, Lasker Scholars will receive appointments for up to 5-7 years as tenure-track investigators within the NIH Intramural Research Program with independent research budgets. In the second phase, successful scholars will receive up to 3 years of NIH support for their research at an extramural research facility; or, the Scholar can be considered to remain as an investigator within the intramural program.
Funding Opportunity RFA-NS-23-026 from the NIH Guide for Grants and Contracts. Reissue of RFA-NS-22-011 to comply with DMSP. No additional receipt dates added. This funding opportunity announcement (FOA) supports efforts to disseminate resources and to integrate them into neuroscience research practice. Projects should be highly relevant to specific goals of the BRAIN Initiative, goals that are described in the planning document "BRAIN 2025: A Scientific Vision." They should engage in one or more of the following activities: distribution of tools and reagents; user training on the usage of new technologies or techniques; providing access to existing technology platforms and specialized facilities; minor improvements to increase the scale/efficiency of resource production and delivery; minor adaptations to meet the needs of a user community. Applications strictly focused on technology or software development, rather than dissemination of an existing resource, are not responsive to this FOA. Refinements to microscopes or tools necessary to customize them to the experimental needs of the end users is allowed. Projects should address compelling needs of neuroscience researchers working toward the goals of the BRAIN 2025 report that are otherwise unavailable or impractical in their current form.
Notice NOT-AR-23-006 from the NIH Guide for Grants and Contracts
Notice NOT-TR-23-012 from the NIH Guide for Grants and Contracts
Notice NOT-CA-23-060 from the NIH Guide for Grants and Contracts
Funding Opportunity RFA-ES-23-001 from the NIH Guide for Grants and Contracts. The National Institute of Environmental Health Sciences (NIEHS) is announcing the continuation of the Superfund Hazardous Substance Research and Training Program, referred to as Superfund Research Program (SRP) Centers. SRP Center grants will support problem-based, solution-oriented research Centers that consist of multiple, integrated projects representing both the biomedical and environmental science and engineering disciplines; as well as cores tasked with administrative (which includes research translation), data management and analysis, community engagement, research experience and training coordination, and research support functions. The scope of the SRP Centers is taken directly from the Superfund Amendments and Reauthorization Act of 1986, and includes: (1) advanced techniques for the detection, assessment, and evaluation of the effect on human health of hazardous substances; (2) methods to assess the risks to human health presented by hazardous substances; (3) methods and technologies to detect hazardous substances in the environment; and (4) basic biological, chemical, and physical methods to reduce the amount and toxicity of hazardous substances.
Funding Opportunity PAR-23-168 from the NIH Guide for Grants and Contracts. The objective of this funding opportunity announcement (FOA) is to stimulate research in 1) discovery and development of novel, small molecules for their potential use in studying disease treatment relevant to psychiatric disorders; and 2) to generate new insight into the biology of relevant diseases and processes that have yet to be validated as important drug targets.
Notice NOT-AG-23-017 from the NIH Guide for Grants and Contracts
Notice NOT-GM-23-041 from the NIH Guide for Grants and Contracts
Funding Opportunity RFA-AI-23-023 from the NIH Guide for Grants and Contracts. The purpose of this Funding Opportunity Announcement (FOA) is to support applications for high-priority, regionally relevant infectious diseases research by international investigators in resource-constrained countries. Applicant organizations must be headquartered in foreign (non-U.S.) resource-constrained countries (i.e. low-income economies, lower-middle-income economies, and upper-middle-income economies by World Bank Classification). Applicant organizations headquartered in low- and lower-middle income economy countries are particularly encouraged to apply. Eligibility status of applicant organizations will be determined by the World Bank Classification list at the time of application submission.
Notice NOT-DE-23-009 from the NIH Guide for Grants and Contracts